What are the typical ECHO (Echocardiography) findings in cardiac amyloidosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Echocardiographic Findings in Cardiac Amyloidosis

Echocardiography reveals a constellation of structural and functional abnormalities in cardiac amyloidosis, with the hallmark finding being increased left ventricular wall thickness (≥12 mm) combined with a small LV cavity, biatrial enlargement, and a characteristic apical sparing pattern on longitudinal strain imaging. 1

Structural Abnormalities

Left Ventricular Changes

  • Increased LV wall thickness ≥12 mm is the cardinal structural finding, often presenting with concentric hypertrophy and a small cavity size 1, 2
  • The myocardial walls frequently demonstrate a "granular sparkling" or hyperechogenic appearance (present in 55-89% of cases), corresponding to scattered amyloid deposits histopathologically 1, 3
  • This granular appearance, while characteristic, is not universally present and does not correlate with specific amyloid subtypes 3

Atrial and Valvular Involvement

  • Biatrial enlargement is present in 89% of cases and is typically disproportionate to the degree of ventricular dysfunction 1, 4
  • Thickened cardiac valves without significant stenosis are characteristic, along with increased atrial septal thickness 1, 2
  • Right ventricular free wall thickening is commonly observed and should raise suspicion when present with LV hypertrophy 1, 4

Pericardial Findings

  • Pericardial effusion occurs in approximately 67% of cases, typically small and generalized 1, 3

Functional Abnormalities

Diastolic Dysfunction

  • Restrictive transmitral Doppler filling pattern is the hallmark functional abnormality, characterized by markedly elevated E wave, reduced A wave, and decreased deceleration time 1
  • 69-100% of patients demonstrate restrictive filling patterns (E/A ≥2.0, E/e' ≥15), reflecting severe diastolic dysfunction 5, 4, 6
  • Reduced E' wave velocity on tissue Doppler imaging indicates impaired myocardial relaxation 1

Systolic Function and Strain Imaging

  • LV ejection fraction is typically preserved or only mildly reduced (mean 49-50%) until late-stage disease, despite significant myocardial infiltration 5, 4, 6
  • Reduced longitudinal strain with apical sparing pattern is highly characteristic, with an apical-to-basal strain ratio >2.1 being highly suggestive of cardiac amyloidosis 1, 2
  • All patients with biopsy-proven cardiac amyloidosis demonstrate apical sparing on longitudinal strain echocardiography when deformation imaging is performed 4
  • The "bulls-eye" appearance on strain mapping, showing preserved apical function with impaired mid-basal segments, is typical 1
  • LV ejection fraction-to-strain ratio >4 is a notable diagnostic feature 1, 2

Tissue Doppler Findings

  • Decreased S' wave measurement on lateral wall tissue Doppler imaging reflects impaired longitudinal systolic function 1
  • Tissue Doppler can detect subtle changes in both systolic and diastolic function that cannot be detected by conventional Doppler flow measurements 5

Critical Diagnostic Integration

ECG-Echo Discordance

  • The combination of low QRS voltage on ECG with increased LV wall thickness on echo (>12 mm) is particularly useful for raising clinical suspicion, as this voltage-to-mass discordance is highly specific for infiltrative disease 1, 2, 7, 8
  • Low voltage is present in approximately 25% of ATTR and 50% of AL amyloidosis cases 8

Temporal Evolution

  • Serial echocardiography reveals that cardiac amyloidosis initially manifests as diastolic LV dysfunction rather than systolic dysfunction 3
  • The final stage is characterized by severe impairment of both systolic and diastolic functions 3
  • Reduced LV distensibility occurs in 78-100% of cases, while reduced contractility appears later (22-44%) 3

Important Clinical Caveats

Limitations of Echocardiography

  • Echocardiography cannot distinguish AL (light chain) from ATTR (transthyretin) cardiac amyloidosis, requiring further testing with monoclonal protein screening and/or nuclear imaging for subtype determination 2, 7
  • When echocardiography shows suggestive findings, proceed immediately with monoclonal protein screening (serum/urine immunofixation, free light chains), NT-proBNP, troponin, and nuclear imaging with bone tracers for ATTR diagnosis 2, 7

Advanced Techniques

  • Speckle-tracking analysis is recommended by multiple international guidelines as part of comprehensive echocardiographic evaluation and provides superior functional and prognostic information compared to tissue Doppler imaging 2, 5
  • LV longitudinal strain and cyclic variation of myocardial integrated backscatter may be the best predictors of adverse outcomes 6

When to Proceed to Advanced Imaging

  • Cardiac MRI should be performed when echocardiography shows suggestive but not definitive findings to enable tissue characterization and differentiate amyloidosis from other causes of LV hypertrophy 2, 7
  • The European Society of Cardiology proposes an Integrated Wall Thickness (IWT) echocardiographic score, where values ≥8 combined with positive bone scintigraphy can be diagnostic of ATTR cardiac amyloidosis 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cardiac MRI vs Echocardiography for Diagnosing Cardiac Amyloidosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Echocardiographic assessment of the cardiac amyloidoses.

Circulation journal : official journal of the Japanese Circulation Society, 2015

Guideline

Diagnosis of Cardiac Amyloidosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management Approach for Low Voltage on ECG

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.